Cargando…
Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine
Targeted therapies have reshaped the landscape of the development of cancer therapeutics. Recent biomarker‐driven, tissue‐agnostic clinical trials represent a significant paradigm shift in precision cancer medicine. Despite their growth in preclinical and clinical studies, to date only a few biomark...
Autores principales: | Seligson, Nathan D., Knepper, Todd C., Ragg, Susanne, Walko, Christine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891377/ https://www.ncbi.nlm.nih.gov/pubmed/32535906 http://dx.doi.org/10.1002/cpt.1946 |
Ejemplares similares
-
Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review
por: Mansinho, André, et al.
Publicado: (2022) -
A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics—Leveraging Principles of Systems Biology
por: Brumfield, Kyle D., et al.
Publicado: (2023) -
Drug Development in Tissue-Agnostic Indications
por: du Rusquec, Pauline, et al.
Publicado: (2021) -
Precision medicine becomes reality—tumor type-agnostic therapy
por: Yan, Li, et al.
Publicado: (2018) -
MapperPlus: Agnostic clustering of high-dimension data for precision medicine
por: Datta, Esha, et al.
Publicado: (2023)